Key result
DanGer Shock trial eligibility is linked to ~35-point higher 180-day mortality in real-world cardiogenic shock.
Why the study?
What proportion of a real-world cohort of cardiogenic shock patients meets the DanGer Shock trial eligibility criteria, and how do their baseline characteristics, complications, and 180-day all-cause mortality compare to trial participants and ineligible registry patients?
Cohort (n=721)
No
What proportion of a real-world cohort of cardiogenic shock patients meets the DanGer Shock trial eligibility criteria, and how do their baseline characteristics, complications, and 180-day all-cause mortality compare to trial participants and ineligible registry patients?
Only 30.5% of real-world STEMI-related cardiogenic shock patients (and 16.2% of all cardiogenic shock patients) met DanGer Shock eligibility criteria, and eligible real-world patients had substantially higher resuscitation rates and 180-day mortality (71.8% vs. 52.1%) than trial participants, limiting the broad generalizability of the trial's findings.
Answers are grounded in this paper and cite their sources.
DanGer Shock eligibility captured a high-mortality minority of real-world patients; leaves open broad applicability of trial benefits to unselected cardiogenic shock cohorts.
BACKGROUND: The DanGer Shock trial investigated the effects of adding a microaxial flow pump to guideline-recommended therapy in patients with ST-elevation myocardial infarction (STEMI)-related cardiogenic shock (CS), finding a lower all-cause mortality at 180 days in the intervention group. METHODS: DanGer Shock eligibility criteria were applied to the prospective single-center PREPARE CardShock registry, which consecutively enrolled 721 patients between April 2019 and August 2024 with advanced CS-classified as stages C to E according to the SCAI shock classification-who were on vasoactive medication and underwent cardiac catheterization. RESULTS: Among 721 patients in the registry, 384 (53.3%) had STEMI-related CS. Of those, 117 (30.5%) met DanGer Shock trial eligibility criteria, accounting for 16.2% of the registry cohort. Median age of the eligible patients was 68 years (interquartile range [IQR]: 58-78), and 62.4% were male, compared to 68 years (IQR: 60-76) and 79.2% in DanGer Shock. PREPRARE-CS DanGer Shock eligible patients had a higher median systolic blood pressure (SBP) (92 mmHG [78-107] vs. 83 mmHG, [72-91]) and higher median lactate levels (5.2 mmol/L [3.6-7.6] vs. 4.6 mmol/L [3.3-7.0]) at baseline, and were more frequently resuscitated (56.4% vs. 20.3%). Device use was 42.7% in eligible patients. Renal replacement therapy (RRT) was more frequent among trial participants (34.4% vs. 17.1%). The 180-day mortality rate among eligible patients was 71.8%, compared to 52.1% in trial participants. CONCLUSIONS: Among STEMI-related CS patients in our cohort, only one-third met the DanGer Shock eligibility criteria. Consequently, trial outcomes may not be broadly applicable.
No takes yet. Share an insight, caveat, or question.
Planka et al. (2025) conducted a cohort in Cardiogenic shock (SCAI shock stages C to E) (n=721). DanGer Shock trial eligibility criteria in STEMI-related cardiogenic shock vs. STEMI-related cardiogenic shock patients ineligible for DanGer Shock (or published DanGer Shock trial cohort) was evaluated on All-cause mortality at 180 days (p=<0.001). DanGer Shock eligibility criteria were met by 30.5% of STEMI-related cardiogenic shock patients, who had higher 180-day mortality than ineligible patients.
Synapse has enriched 10 related papers. Consider them for comparative context: